Amgen Inc. (AMGN) Stock Analysis
A live, multi-source view of Amgen Inc. (AMGN): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 31,500 employees · amgen.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Amgen Inc. (AMGN) had a market capitalization of $236.38B, a trailing P/E of 27.6 (forward 17.9), a dividend yield of 2.31% and a beta of 0.43; the shares traded in a 52-week range of $269.77 – $447.03 (58.5% over the year).
- Market cap
- $236.38B
- Enterprise value
- $279.70B
- Trailing P/E
- 27.6
- Forward P/E
- 17.9
- PEG ratio
- 2.14
- Price / book
- 20.22
- EPS (trailing)
- $15.87
- EPS (forward)
- $24.41
- Dividend yield
- 2.31%
- Payout ratio
- 60.9%
- Ex-dividend date
- 2026-08-21
- 52-week range
- $269.77 – $447.03
- 52-week change
- 58.5%
- Beta
- 0.43
- Average volume
- 2.7M
- Shares outstanding
- 540.6M
- Short % of float
- 2.23%
- Profit margin
- 23.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Amgen Inc. (AMGN) last closed at $382.47 (the last completed close before that scan).
Technicals at the scan: RSI 33 (neutral territory), price -10.5% versus its 20-day average, 20-day versus 50-day average spread +7.2%, MACD histogram -8.26.
Sentiment inputs: 45% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; Reddit mentions 0% over 24 hours; analyst consensus score 57/100.
Next scheduled company event: in 53 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 5 sells of AMGN; corporate insiders filed 0 buys and 6 sells (7 distinct filers, latest disclosure 2026-09-05). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: David J. Taylor (0B/2S), Rachna Khosla (0B/2S), Nancy A. Grygiel (0B/2S), Derek Miller (0B/2S), Sheldon Whitehouse (0B/1S), Tommy Tuberville (0B/1S). Who is trading what
RapidTradeView pick record
AMGN has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Amgen Inc. (AMGN) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell AMGN.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.